anti-CD19 CAR T-cell therapy

June 8, 2017June 8, 2017

T-Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 Trial

News

Recently announced data from a Phase 1 trial for investigational T-cell therapy JCAR017 shows a high response rate for patients with relapsed or refractory CD19+ aggressive B-cell non-Hodgkin lymphoma (NHL), ... Read more

May 30, 2017

FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) seeking the approval of axicabtagene ciloleucel (KTE-C19) for the treatment of refractory aggressive non-Hodgkin’s ... Read more

March 24, 2017March 24, 2017

CAR T-cell Therapy Induces Durable Complete Responses in Some Non-Hodgkin Lymphoma Patients

News

Kite Pharma’s anti-CD19 CAR T-cell therapy is a promising approach to treat patients with relapsed or refractory non-Hodgkin lymphoma, according to data from a Phase 1 clinical trial. James N. ... Read more